MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP). It is being developed by Merck & Co.

Property Value
dbo:abstract
  • MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP). It is being developed by Merck & Co. (en)
dbo:casNumber
  • 869901-69-9
dbo:chEMBL
  • 1237018
dbo:fdaUniiCode
  • LJ8U884TM5
dbo:pubchem
  • 11554427
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-06-13 12:50:07Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 25019159 (xsd:integer)
dbo:wikiPageLength
  • 2613 (xsd:integer)
dbo:wikiPageModified
  • 2018-08-29 15:39:03Z (xsd:date)
dbo:wikiPageOutDegree
  • 7 (xsd:integer)
dbo:wikiPageRevisionID
  • 857101191 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP). It is being developed by Merck & Co. (en)
rdfs:label
  • MK-2048 (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is foaf:primaryTopic of